Recruiting

Communication Training

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT05940272

Conditions

Lymphoma, B-Cell

Lymphoma

Large-cell Lymphoma

Large B-cell Lymphoma

DLBCL - Diffuse Large B Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Hematolo-GIST Training

Participants Appointment

Study Details

Brief summary:

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

Conditions

Lymphoma, B-Cell

Lymphoma

Large-cell Lymphoma

Large B-cell Lymphoma

DLBCL - Diffuse Large B Cell Lymphoma

Study ID

NCT05940272

Start date

Jul 3, 2023

Status verified date

Oct, 2025

Completion date

Jul 3, 2028

Anticipated

Primary completion date

Jul 3, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Providers

  • Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)

Patients

  • Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)
  • Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
  • Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT)
  • Self-identify as Black and/or White
  • Per medical record, 18 years of age or older
  • Per self-report, fluent in English\*\*

  • Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:

1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
2. What is your preferred language for healthcare? (must respond English)

Exclusion Criteria:

Providers

  • Per self-report, planning to leave the cancer center in the next 12 months

Patients

  • Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
  • Per research staff judgment and/or self-report, too ill or weak to complete study procedures
  • Per medical record or self-report, receiving hospice care at the time of enrollment

Study Design

Enrollment

48 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Hematologists

Hematologists will be recruited from the lymphoma clinics at MSK

experimental: Participants Patients

Participant patients are being treated by a hematologic oncologist participating in this study

Interventions

Hematolo-GIST Training

Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.

Participants Appointment

Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.

Primary outcome measure

  • Feasibility of the Hematolo-GIST intervention among hematologists and participants [ Time Frame: Up to 1 year ]

Central Contacts and Locations

Central contacts

Revecca Saracino, PhD

646-888-0263jamesr@mskcc.org

Locations

Memorial Sloan Kettering Cancer Center (All protocol activities)

Recruiting

New York, New York, United States, 10065

Contacts

Kelly McConnell, PhD

646-888-0026

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Oct 9, 2025

Last verified

Oct, 2025

Keywords

  • oncologist
  • hemotologic oncologist
  • lymphoma
  • large cell lymphoma
  • large b-cell lymphoma
  • DLBCL
  • Diffuse Large B Cell Lymphoma
  • Mediastinal B-Cell Diffuse Large Cell Lymphoma
  • Hematolo-GIST
  • 23-164
  • Memorial Sloan Kettering Cancer Center

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2025-10-09.